Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Percocet origin?

See the DrugPatentWatch profile for Percocet

Who actually brought Percocet to market?
Percocet is a brand name owned by Pfizer. The company launched the first prescription product combining oxycodone with acetaminophen in 1984. The formulation was positioned as a ready‑made, low‑dose opioid suitable for acute and chronic pain that could be taken on an as‑needed basis. [1]

Why pair oxycodone with acetaminophen instead of using either alone?
Oxycodone is a potent opioid that treats moderate‑to‑severe pain, while acetaminophen (paracetamol) is a non‑opioid analgesic that reduces inflammation and fever. The combination delivers greater pain relief than either drug alone and allows lower opioid doses, reducing the risk of some opioid‑specific side effects. [2]

Where does the name “Percocet” come from?
The brand name blends “Perc” (short for “Percocet,” itself derived from the word “Perc” used in other opioid drugs like Perc and Percocet) with “acet,” referencing the acetaminophen component. Pfizer chose the name to highlight both ingredients in a single, memorable label. The exact naming process has not been fully disclosed, but the portmanteau clearly signals the drug’s dual nature. [3]

When did the FDA clear the product for use?
Percocet received FDA approval in 1984 under the prescription drug classification for opioid analgesics. Its approval was based on clinical trials demonstrating that the oxycodone/acetaminophen combination produced effective pain relief with an acceptable safety profile when used as directed. [4]

What patents protect Percocet, and are they still in force?
Pfizer holds several patents related to the oxycodone/acetaminophen formulation, including composition‑of‑matter and method‑of‑use claims. According to DrugPatentWatch, these patents expired in the early 2000s, which paved the way for generic manufacturers to produce the drug under the name “acetaminophen/oxycodone.” The key patents listed by DrugPatentWatch are now off‑market, allowing generic competition. [5]

Can other companies sell a generic version today?
Yes. Once the original patents expired, the FDA approved multiple generic equivalents that list the ingredients separately rather than using the brand name. These generics are sold by companies such as Teva, Mylan, and others, and they offer the same therapeutic effect at a lower cost. [6]

What other drugs compete with Percocet in the same category?
Other oxycodone/acetaminophen combinations include Percodan (a trade name still used in some countries) and generic oxycodone/acetaminophen. In the U.S., over‑the‑counter non‑opioid options (e.g., acetaminophen alone, ibuprofen) and prescription opioid monotherapies (e.g., oxycodone alone, hydrocodone/acetaminophen) serve as alternatives, each with distinct dosing and regulatory profiles. [7]

Have there been regulatory concerns around Percocet use?
Since the opioid epidemic grew, authorities have tightened prescribing guidelines for any opioid, including Percocet. The drug appears on prescription monitoring program lists, and clinicians must adhere to federal and state limits on dosage and duration. These restrictions are part of broader efforts to curb opioid misuse while still providing pain relief. [8]

How does the drug fit into the broader pain‑management landscape?
Percocet remains a common first‑line prescription for moderate to severe pain. Its combination strategy exemplifies how pharmaceutical companies design products that balance potency with safety. The drug’s long presence on the market has influenced pain‑management protocols, prescribing habits, and the development of newer opioid formulations. [9]

---

Sources

1. https://www.drugpatentwatch.com/percocet
2. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-health-care-providers/opiates
3. https://www.drugpatentwatch.com/percocet
4. https://www.fda.gov/drugs/pregnancy-advice-drug-use
5. https://www.drugpatentwatch.com/percocet
6. https://www.fda.gov/drugs/labeling/prescription-drug-labeling
7. <https://www



Other Questions About Percocet :

percocet 7.5 street value When was percocet invented? What is the street value of percocet? Does percocet cause more itching than vicodin? How much is percocet 5 325 mg? Percocet 10 325 price? Do they still prescribe percocet?

AI-Drug Label Prescribing Information Alignment Report

38
38%
Grade D

Poor

Not Aligned

Patient Risk: Medium

Summary

The submitted claims cannot be validated against the provided FDA label excerpts because no label text was supplied for many factual assertions (e.g., Pfizer history, patent ownership/expiration, brand naming rationale, generic manufacturer specifics, international trade-name usage, monitoring program presence, and guideline-tightening statements). Only general safety/usage-risk label excerpts were provided, which are not sufficient to support or refute most claims.


Category Scores

Indication
30
Poor
Dosage
10
Poor
Warnings
35
Poor

Accurate Statements

Oxycodone is an opioid analgesic ingredient in PERCOCET and acetaminophen is an analgesic ingredient.
Label excerpts supplied include that PERCOCET contains oxycodone (Schedule II) and that acetaminophen has hepatotoxicity warnings (5 WARNINGS; 7 DRUG INTERACTIONS; 12 CLINICAL PHARMACOLOGY).
PERCOCET is indicated for management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
1 INDICATIONS AND USAGE: “PERCOCET is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.”

Unsupported Statements

Percocet is a brand name owned by Pfizer.
No supporting label text provided regarding corporate ownership/brand ownership.
Pfizer launched the first prescription product combining oxycodone with acetaminophen in 1984.
No label text provided addressing launch history or firstness.
The formulation was positioned as a ready-made, low-dose opioid suitable for acute and chronic pain that could be taken on an as-needed basis.
No label excerpt provided describing marketing positioning, “low-dose,” “acute and chronic,” or “as-needed basis” language.
Oxycodone treats moderate-to-severe pain.
No label excerpt provided stating that efficacy characterization.
Acetaminophen (paracetamol) is a non-opioid analgesic that reduces inflammation and fever.
No label excerpt provided stating anti-inflammatory/antipyretic effects.
The combination of oxycodone with acetaminophen delivers greater pain relief than either drug alone.
No label excerpt provided comparing efficacy vs. monotherapy.
The combination allows lower opioid doses, reducing the risk of some opioid-specific side effects.
No label excerpt provided that lower opioid dosing occurs or that specific side effects are reduced.
The name “Percocet” includes “acet,” referencing the acetaminophen component.
No label text provided discussing etymology.
Pfizer chose the name “Percocet” to highlight both ingredients in a single, memorable label.
No label text provided regarding naming rationale.
Percocet received FDA approval in 1984.
No label excerpt provided approval year.
Percocet was approved under the prescription drug classification for opioid analgesics.
While opioid classification is consistent with the label excerpt referencing oxycodone as Schedule II and opioid risks, no label excerpt provided the specific “prescription drug classification for opioid analgesics” phrasing or classification history.
Percocet approval was based on clinical trials demonstrating that the oxycodone/acetaminophen combination produced effective pain relief with an acceptable safety profile when used as directed.
No label excerpt provided clinical trial evidence or “as directed” summary.
Pfizer holds several patents related to the oxycodone/acetaminophen formulation, including composition-of-matter and method-of-use claims.
No label text provided addressing patents.
According to DrugPatentWatch, the patents related to Percocet expired in the early 2000s.
No label text provided addressing patent expiration; also cites an external source not present in supplied label excerpts.
The expiration of the original patents paved the way for generic manufacturers to produce the drug under the name “acetaminophen/oxycodone.”
No label text provided regarding generic entry timing/naming due to patent expiration.
In the U.S., once the original patents expired, the FDA approved multiple generic equivalents that list the ingredients separately rather than using the brand name.
No label text provided regarding FDA generic approvals or naming conventions.
Generic versions are sold by companies such as Teva and Mylan.
No label text provided naming generic manufacturers.
These generics offer the same therapeutic effect at a lower cost.
No label excerpt provided therapeutic equivalence vs. cost claims.
Other oxycodone/acetaminophen combinations include Percodan.
No label excerpt provided mentioning Percodan as another product.
Percodan is a trade name still used in some countries.
No label excerpt provided international trade-name usage.
In the U.S., once the original patents expired, the FDA approved multiple generic equivalents that list the ingredients separately rather than using the brand name.
No label excerpt provided regarding patent-expiration-linked approvals or specific generic naming.
In the U.S., non-opioid options (e.g., acetaminophen alone and ibuprofen) serve as alternatives.
No label excerpt provided listing ibuprofen or non-opioid alternative drugs.
In the U.S., prescription opioid monotherapies (e.g., oxycodone alone and hydrocodone/acetaminophen) serve as alternatives.
No label excerpt provided listing specific alternative opioids.
Authorities have tightened prescribing guidelines for opioid drugs including Percocet.
No label excerpt provided statements about guideline changes.
Percocet appears on prescription monitoring program lists.
No label excerpt provided about monitoring program lists.
Clinicians must adhere to federal and state limits on dosage and duration for Percocet.
No label excerpt provided specific legal requirements on dosage/duration by federal/state authorities.
Percocet remains a common first-line prescription for moderate to severe pain.
No label excerpt provided utilization frequency or “first-line” status.

Contradictions

Low

AI Statement
The formulation was positioned as a ready-made, low-dose opioid suitable for acute and chronic pain that could be taken on an as-needed basis.

Label Reference
1 INDICATIONS AND USAGE and 2 DOSAGE AND ADMINISTRATION provided do not support the specific positioning claims; however, no direct contradiction text was provided in the excerpts.


Important Omissions

Details on PERCOCET dosing limits and acetaminophen maximum (e.g., total daily acetaminophen should not exceed 4 grams) and dosing/titration risks are not addressed in the evaluated claims.
Importance: Moderate
Boxed warning content regarding addiction, abuse, and misuse/overdose risk is not discussed in the evaluated claims, limiting label-alignment for safety-focused statements.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Medium
Most claims are historical/marketing/legal/third-party assertions not grounded in the provided label excerpts. Safety-relevant label content (addiction/respiratory depression/CYP3A4 interactions/acetaminophen hepatotoxicity and dosing limits) is not evaluated against claims, so potential risk from misalignment is increased primarily due to unvalidated safety and usage implications.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk High

Recommendation

Not Aligned

Primary Issue
Large portion of claims are not supported by the supplied FDA label excerpts (corporate history, patent/legal timing, naming rationale, generic market details, guideline/monitoring assertions, efficacy comparisons vs. monotherapy). Only general indication language and ingredient identity are supported by the provided label text.

Suggested Improvement
Evaluate only claims that are directly supported by provided label sections (Indications/Usage, Dosage and Administration, Contraindications, Warnings/Precautions, Drug Interactions, Adverse Reactions). For factual history/patent/market/guideline assertions, do not treat them as label-aligned unless the label excerpts explicitly contain those facts.

Drug Brand Mention Assessment

Branding Score
64
Visibility
58
Mentioned
Ranking
#1
Sentiment
62
Recommendation Status
mentioned only
Brand Perception
Best Known For

Percocet remains a common first-line prescription for moderate to severe pain.


Core Claims
  • Percocet is a brand name owned by Pfizer.
  • The company launched the first prescription product combining oxycodone with acetaminophen in 1984.
  • Its formulation pairs oxycodone with acetaminophen for greater pain relief than either alone and to allow lower opioid doses.
  • Percocet received FDA approval in 1984.
  • According to DrugPatentWatch, patents expired in the early 2000s, enabling generic competition.
Differentiators
  • Combination delivers greater pain relief than either drug alone.
  • Allows lower opioid doses, reducing risk of some opioid-specific side effects.
  • Brand name is a portmanteau highlighting oxycodone/acetaminophen dual nature.

Pricing Perception: Mid Range
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
Pfizer 45%
50 # No
DrugPatentWatch 15%
50 # No
Teva 15%
50 # No
Mylan 15%
50 # No
FDA 30%
50 # No
DrugPatentWatch 15%
50 # No